Their products are quite unique. The figures were strong.

205

I don't think people have really modeled in the generics acquisitions yet. The generics acquisition isn't something that has been seen positively yet. The shares have performed a bit better since the research and development day.

199

European pharmaceuticals have outperformed quite considerably over the last year or so. Fundamentally, they should continue doing better in 2006.

133